Browsing: China Medical System Holdings Limited

CMS: Initial Prescriptions for Silevimig Injection, the World’s First Bispecific Antibody Against Rabies, Issued in China

BioTech September 9, 2026

On 9 September, China Medical System Holdings Limited (867.HK/8A8.SG) (CMS or the Group) is pleased to announce that the initial…

CMS (867.HK/8A8.SG): Innovative Drug Lumirix(R) Approved in China for Additional Indication of Atopic Dermatitis (AD)

BioTech September 4, 2026

China Medical System Holdings Limited (CMS or the Group) is pleased to announce that its subsidiary, Dermavon Holdings Limited (Dermavon,…

CMS: Class 1 Innovative Drug Silevimig Injection Approved in China, Becoming the World’s First Bispecific Antibody for Passive Immunization Against Rabies

BioTech June 22, 2026

China Medical System Holdings Limited (867.HK/8A8.SG) (CMS, or the Group) is pleased to announce that, the New Drug Application for…

CMS’s (867.HK/8A8.SG) Self-developed Innovative INHBE-Targeting siRNA Drug CMS-D008 Presents Its Preclinical Results at the ADA Scientific Sessions

HealthCare June 8, 2026

China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that the preclinical results of its self-developed…